Artificial Intelligence (AI) in Epidemiology Market (By Deployment: Web-based, Cloud-based; By Application Infection: Prediction and forecasting, Disease and syndromic surveillance; By End-use: Government and State Agencies, Research labs, Pharmaceutical and Biotechnology Companies, Healthcare Providers) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Epidemiology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Artificial Intelligence (AI) in Epidemiology Market, by Deployment, 2024-2033
8.1.1 Web-based
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Cloud-based
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. Artificial Intelligence (AI) in Epidemiology Market, by Application Infection, 2024-2033
9.1.1. Prediction and Forecasting
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Disease and Syndromic Surveillance
9.1.2.1. Market Revenue and Forecast (2021-2033)
10.1. Artificial Intelligence (AI) in Epidemiology Market, by End-use, 2024-2033
10.1.1. Government and State Agencies
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Research labs
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Pharmaceutical and Biotechnology Companies
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Healthcare Providers
10.1.4.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.1.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.1.3. Market Revenue and Forecast, by End-use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.1.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.1.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.2.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.2.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.2.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.2.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.2.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.2.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.3.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.3.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.3.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.3.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.3.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.3.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.4.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.4.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.4.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.4.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.4.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.5.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.5.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Deployment (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Application Infection (2021-2033)
11.5.5.3. Market Revenue and Forecast, by End-use (2021-2033)
12.1. Cerner Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cognizant
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. eClinical Works Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Alphabet Inc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Intel Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Epic Systems Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Microsoft Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Meditech
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Komodo Health
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Siemens Healthineers
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample